Výsledky vyhledávání - "Docetaxel-Prednisone Regimen"

710 DOSE FINDING AND EFFICACY PHASE 2 STUDY OF INECALCITOL, A NEW VDR AGONIST, IN COMBINATION WITH DOCETAXEL-PREDNISONE REGIMEN FOR CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS (PTS)

Autor: Jean-Marc Ferrero, J. Ayllon, Gael Deplanque, Jean-Francois Dufour-Lamartinie, Jacques Medioni, Stéphane Oudard, Tristan Maurina, Jean-Michel Rodier, Eric Raymond, Stephanie Renaux

Publikováno v: Journal of Urology. 185

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ba4a7eec63043aa019e774f94e5c4cb3
https://doi.org/10.1016/j.juro.2011.02.1678

Zobrazit plný text záznamu

Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for patients (pts) with castration-resistant prostate cancer (CRPC)

Autor: J-M Ferrero, J. Allyon, Stéphane Oudard, Jacques Medioni, Jean-Michel Rodier, S. Renaux, Gael Deplanque, Eric Raymond, J.F. Dufour-Lamartinie, Tristan Maurina

Publikováno v: Journal of Clinical Oncology. 29:4605-4605

4605 Background: Inecalcitol is a novel vitamin D receptor (VDR) agonist which shows high antiproliferative effects in human cancer cell lines and a 100-fold lower hypercalcemic activity than calci...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66f07917b00adae844773c86a557cee4
https://doi.org/10.1200/jco.2011.29.15_suppl.4605

Zobrazit plný text záznamu

Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for castration-resistant prostate cancer (CRPC) patients (pts)

Autor: J. Allyon, S. Renaux, Jacques Medioni, J.F. Dufour-Lamartinie, Gael Deplanque, J-M Ferrero, Eric Raymond, Stéphane Oudard, Tristan Maurina, Jean-Michel Rodier

Publikováno v: Journal of Clinical Oncology. 29:142-142

142 Background: Inecalcitol is a novel vitamin D receptor (VDR) agonist which shows high antiproliferative effects in human cancer cell lines and a 100-fold lower hypercalcemic activity than calcitriol the natural ligand of VDR. Methods: Escalating d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::00e1ef50eaaa58055fb788138397e9f2
https://doi.org/10.1200/jco.2011.29.7_suppl.142

Zobrazit plný text záznamu

430 Dose finding of inecalcitol, a new VDR agonist, in combination with docetaxel–prednisone regimen for castrate-resistant prostate cancer (HRPC) patients (pts)

Autor: J. Medioni, T. Maurina, J.M. Rodier, S. Renaux, J-M Ferrero, G. Deplanque, G. Allyon, Eric Raymond, Stéphane Oudard, J.F. Dufour-Lamartinie

Publikováno v: European Journal of Cancer Supplements. 8:136

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::807c3f83c0fe8bfabf91a2a0fb87b7b2
https://doi.org/10.1016/s1359-6349(10)72137-6

Zobrazit plný text záznamu

POD-11.01: Dose Finding and Safety Analysis of Inecalcitol in Combination with Docetaxel-Prednisone Regimen in Hormone-Refractory Prostate Cancer (HRPC) Patients (PTS)

Autor: G. Deplanque, J. Medioni, J. Allyon, S. Oudard, S. Kalla, J. Ferrero, J.M. Rodier, T. Maurina, E. Raymond, J.F. Dufour-Lamartinie

Publikováno v: Urology. 74:S34

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::670f0f279933e8cea8ee9d5279f80a78
https://doi.org/10.1016/j.urology.2009.07.1099

Zobrazit plný text záznamu

7030 Dose finding and safety analysis of inecalcitol in combination with docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients (pts)

Autor: J-M Ferrero, Stéphane Oudard, S. Kalla, J. Medioni, T. Maurina, G. Deplanque, J.F. Dufour-Lamartinie, J. Allyon, J.M. Rodier, Eric Raymond

Publikováno v: European Journal of Cancer Supplements. 7:415

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::efe6095bdad6258553de5cf1f95488ce
https://doi.org/10.1016/s1359-6349(09)71408-9

Zobrazit plný text záznamu

Dose finding and safety analysis of inecalcitol in combination with a docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients

Autor: J. Allyon, Tristan Maurina, Eric Raymond, Stéphane Oudard, J.F. Dufour-Lamartinie, Gael Deplanque, Jacques Medioni, J-M Ferrero, S. Kalla, J.M. Rodier

Publikováno v: Journal of Clinical Oncology. 27:5151-5151

5151 Background: Inecalcitol is a novel synthetic vitamin D3 analogue with potent antiproliferative effects in human cancer cell lines and a 100-fold lower hypercalcemic activity than calcitriol in animal models. Methods: Escalating dosages of inecal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f7da8d6237968be8c225aee7dce65730
https://doi.org/10.1200/jco.2009.27.15_suppl.5151

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání